Introduction
Breast fibroepithelial lesions (FELs) are composed of biphasic proliferation of both epithelial and stromal elements and comprise a wide spectrum of tumors ranging from indolent fibroadenomas (FAs) to malignant phyllodes tumors (PTs). 1 Although FAs are common benign tumors and are usually managed conservatively, PTs are rare (accounting for w2.5% of all mammary FELs and for 1% of all breast cancers) and may recur locally or even metastasize to distant sites. 1 The histologic distinction between FAs and PTs on core needle biopsy (CNB) can be challenging. 2 Pathologists may designate a FEL and add a comment of concern such as "cannot rule out phyllodes"
or "increased stromal cellularity" if features of phyllodes are present but not definitive. 3 However, the exact characterization of a FEL is clinically important as the management may range from observation to wide surgical resection (! 1 cm margin). 2, 4 As it may be impossible to distinguish FA from benign or borderline PT on CNB owing to overlapping histologic features, 2, 3, 5 excision is recommended in many patients, resulting in potential overtreatment. 2, 5, 6 A selective surgical approach based on clinical, radiologic, and pathologic features is therefore recommended. 4, 7 FAs and PTs share not only histologic similarities, but also genetic features. 8 Recurrent somatic mutations affecting exon 2 of MED12 have been identified in both lesions. [9] [10] [11] [12] Additionally, recent genomic analyses of FAs and PTs 12 demonstrated that PTs are genetically more advanced and display a higher mutational burden than FAs. 9 Furthermore, there have been reports of progression from FAs to PTs, 8, 13, 14 with MED12 mutation as the founder genetic event and the subsequent acquisition of additional somatic genetic alterations such as TERT promoter mutations in the PTs. 8 Here, we describe the case of a 59-year-old woman initially diagnosed with a FEL with a TERT promoter mutation who refused surgery and presented 13 months later with a disfiguring borderline PT.
Clinical Practice Points
Breast fibroepithelial lesions (FELs) comprise a wide spectrum of tumors ranging from indolent fibroadenomas (FAs) to malignant phyllodes tumors (PTs). The histologic distinction between the 2 on core needle biopsy can be challenging. There is a need for molecular markers to better discriminate subclasses of breast FELs on core needle biopsy to tailor clinical management. Recently, TERT promoter mutations and gene amplifications have been used to differentiate FAs from PTs.
This report describes a 59-year-old woman diagnosed with an FEL of the left breast who refused surgery and presented 13 months later with a disfiguring borderline PT that required mastectomy. Sequencing of the early FEL and of the PT showed MED12 hotspot (c.131G>A) and TERT promoter (c.-124C>T) somatic mutations, suggesting that the lesion at time of the initial biopsy was already a PT. The characterization of somatic mutations on core needle biopsy can help to better characterize FELs and therefore increase diagnostic accuracy.
Case Report
In May 2016, a 59-year-old woman with no personal history of breast or ovarian cancer was diagnosed with polymyositis. Clinical examination revealed an asymmetry of the left breast and a w6-cm palpable mass on the upper external quadrant ( Figure 1A ) but no lymphadenopathies. Mammogram ( Figure 1B ) and ultrasound confirmed a 5.5 Â 5-cm mass in the upper external quadrant of the left breast and a 0.6 Â 0.7-cm mass in the upper external quadrant of the right breast. CNB of both lesions was performed for diagnostic purposes. Histologic examination revealed a FA on the right side (classified as B2-lesion) ( Figure 1C ) and a FEL with increased stromal cellularity on the left side (classified as B3-lesion) ( Figure 1D ). Surgical excision of the FEL lesion was scheduled, but shortly before surgery, the patient canceled the operation and was lost to follow-up.
Thirteen months later (June 2017), the patient presented to the emergency department with disfiguring swelling of the left breast ( Figure 2A ). On physical examination, the left breast was massively enlarged and tender with a flattened nipple, engorged superficial vessels, and deeply erythematous skin ( Figure 2A ). Breast ultrasound and magnetic resonance imaging ( Figure 2B ) showed a 16-cm heterogeneous mass filling the entire left breast with an extensive central fluid collection without suspected lymphadenopathies ( Figure 2B ). A diagnostic puncture of 1200 mL of bloody fluid was sent for cytology and microbiological tests that revealed no bacterial growth and no cellular atypia. CNB showed a myofibroblastic proliferation without an epithelial component. Differential diagnosis included a PT (stromal component only) or a non-specific reactive inflammatory process. After a multidisciplinary discussion, owing to the large size of the tumor, mastectomy was performed. Based on the presence of focal stromal overgrowth, increased mitoses (7 per 10 high powered field) and focally invasive tumor borders ( Figure 2C,D) , the diagnosis of a borderline PT was made on final histology. The patient recovered well, without complications. Thirteen months after treatment, the patient continued to do well with no evidence of disease recurrence.
To correlate the genomic profile of the tumor with its clinical evolution, massively parallel sequencing of 32 genes commonly altered in breast cancer (see Supplemental Table 1 in the online version) was performed and analyzed as previously described, 15 on tissues from the FA (right breast), the FEL, and the PT (left breast).
No somatic mutations were identified in any of the genes recurrently mutated in breast cancer. Subsequently, all 3 lesions were subjected to Sanger sequencing for the MED12 hotspot and for TERT promoter somatic mutations. Again, no mutation was identified in the FA in the right breast ( Figure 3A ). However, we identified a MED12 hotspot (c.131G>A) and TERT promoter (c.-124C>T) mutations in both the early B3 lesion and in the subsequent lesion after 13 months, suggesting the progression of the early lesion. This observation was further supported by their shared copy number alterations on chromosomes 11, 12, and 21, and the subsequent acquisition of copy number loss of AKT1 and TP53 in the later lesion ( Figure 3B ).
Discussion
This 59-year-old woman was diagnosed with a FEL with increased stromal cellularity (B3-lesion). The uncertain malignant potential was discussed with the patient in detail, and surgical excision was scheduled. Given the absence of "cancer cells" on the CNB, the patient perceived the lesion as not dangerous. The patient canceled the scheduled operation, and follow-up was lost. The disfiguring evolution of the breast lesion and the inconclusive diagnosis on the second CNB 13 months later led to a mastectomy without reconstruction.
Currently, there are no absolute criteria to recommend the excision of FELs when definitive diagnosis of a PT is not rendered after CNB. 2, 7 Many authors advocate reliance on pathologists' comments and concordance assessment as important considerations to guide clinical management of FELs. 3, 16 Van Osdol et al recently reported a sensitivity and specificity of 82% and 93%, respectively, for a pathologist comment of concern. 7 Nevertheless, only 18% to 38% of patients who received excision for a FEL had a PT on definitive histology. 3, 17, 18 The sometimes extreme difficulty of distinguishing PTs from cellular FA, particularly in a limited tissue sample of a CNB, has also been acknowledged in the latest World Health Organization classification, 1 which states that in inconclusive cases, the diagnosis of a cellular fibroepithelial neoplasm may be appropriate, recognizing the inability to classify these lesions correctly. 19 Recently, it has been suggested that TERT alterations may assist in the differential diagnosis between FAs and PTs, as TERT vpromoter mutations and gene amplifications are frequent in PTs but are absent in FAs, and their frequency increases according to the grade of the PT (18% in benign, 57% in borderline, and 64% in malignant PTs). 8, 20 Piscuoglio et al concluded that sequencing and gene copy number analysis differentiate FAs from PTs with a 100% specificity and 100% positive predictive value. 8 The finding of a TERT promoter mutation in the early B3 FEL on the left side would suggest it was also a PT. Genomic profiling has also furthered our understanding of the etiopathology of PTs. Pareja et al 21 have recently studied PTs with and without FA-like areas and hypothesized that borderline and malignant PTs might follow 2 distinct evolutionary pathways, according to MED12 status. In the MED12-mutant pathway, MED12 exon 2 mutations are posited to lead to the development of a benign FEL, which, upon the occurrence of additional genetic alterations affecting TERT and/or other cancer gene, may progress to a borderline or malignant PT. In the MED12-independent pathway, borderline or malignant PTs might arise de novo, through acquisition of genetic alterations targeting cancer genes such as TERT and/or EGRF and other tumor suppressor genes. 21 The presence of both the MED12 and TERT mutations in our current case would suggest it likely occurred through the MED12-mutant pathway, followed by the subsequent acquisition of the TERT promoter mutation, as well as additional copy number alterations. The evolution from FA to PTs rarely occurs and has been reported in the literature as a slow process. 22, 23 On the other hand, PTs are often reported as rapidly growing. 24 Whether growth rate differs according to the expression of MED12 is unknown. In the present case, the patient presented with a 5-cm FEL, with MED12 and TERT promoter mutations, which rapidly evolved into a disfiguring borderline PT, which needed mastectomy.
Conclusion
Recent studies have suggested that TERT promoter hotspot mutation and/or amplification may drive PT progression from a benign lesion such as FA, which represents an example of how genomic profiling may inform the clinical management of FELs. The current case demonstrates the natural course of a borderline PT after refusal of surgery. Knowing that the lesion had a TERT mutation and therefore a high likelihood of being a PT might have had encouraged the patient to undergo surgical excision and thus would have spared her the burden of a mastectomy. Further studies are needed to evaluate the impact of massively parallel sequencing on the outcome of patients with FELs.
